All In Biotech

Drug Trial Radar · NCT01368536

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Last checked: Nov 19, 2026Latest source record: Mar 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 975 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

975

Actual

Start

May 2011

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and diabetes mellitus 2.

Conditions

  • Hypertension
  • Stage 2 Hypertension
  • Diabetes

Interventions

  • ValturnaDrug

    Valturna (aliskiren 150 mg/valsartan 160 mg) tablet

  • AmlodipineDrug

    Amlodipine 5 mg and 10 mg capsule

  • ChlorthalidoneDrug

    Chlorthalidone 15 mg and 25 mg capsule

  • Placebo of Valturna TabletDrug

    Matching placebo of valturna tablet

  • Placebo CapsuleDrug

    Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna AloneTime frame: Baseline, 12 weeks

Locations

97 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Athens, Alabama

  • Novartis Investigative Site

    Florence, Alabama

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Montgomery, Alabama

  • Novartis Investigative Site

    Muscle Shoals, Alabama

  • Novartis Investigative Site

    Chandler, Arizona

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Buena Park, California

  • Novartis Investigative Site

    Fair Oaks, California

  • Novartis Investigative Site

    Fresno, California

  • Novartis Investigative Site

    Healdsburg, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Orangevale, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    Roseville, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    West Covina, California

  • Novartis Investigative Site

    Shelton, Connecticut

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Fort Lauderdale, Florida

  • Novartis Investigative Site

    Jupiter, Florida

  • Novartis Investigative Site

    Lauderdale Lakes, Florida

  • Novartis Investigative Site

    North Miami Beach, Florida

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Augusta, Georgia

  • Novartis Investigative Site

    Honolulu, Hawaii

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Gurnee, Illinois

  • Novartis Investigative Site

    Lansing, Kansas

  • Novartis Investigative Site

    Topeka, Kansas

  • Novartis Investigative Site

    Beltsville, Maine

  • Novartis Investigative Site

    Waltham, Massachusetts

  • Novartis Investigative Site

    Wellesley Hills, Massachusetts

  • Novartis Investigative Site

    Brooklyn Center, Minnesota

  • Novartis Investigative Site

    Belzoni, Mississippi

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.